MedTrace Logo

Risk Adapted Therapy in Diffuse Large B Cell Lymphoma

NCT03188198 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-07-06

No results posted yet for this study

Summary

This randomized phase II trial is studying two different combination chemotherapy regimens to compare how well they work in treating patients with diffuse large B-cell lymphoma.

Conditions

  • Large B Cell Lymphoma

Interventions

DRUG

rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim

Sponsors & Collaborators

  • Mansoura University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-01
Primary Completion
2018-06-01
Completion
2019-06-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03188198 on ClinicalTrials.gov